JunSung Lee1, Edlira Hoxha1, Hae-Ri Song1,2,3. 1. Department of Neurosurgery, New York University, School of Medicine, New York, NY, USA. 2. Department of Neurology, New York University, School of Medicine, New York, NY, USA. 3. Brain Tumor Center, Perlmutter Cancer Center, New York University, School of Medicine, New York, NY, USA.
Abstract
Background: The nuclear factor I-A (NFIA) transcription factor promotes glioma growth and inhibits apoptosis in glioblastoma (GBM) cells. Here we report that the NFIA pro-survival effect in GBM is mediated in part via a novel NFIA-nuclear factor-kappaB (NFκB) p65 feed-forward loop. Methods: We examined effects of gain- and loss-of-function manipulations of NFIA and NFκB p65 on each other's transcription, cell growth, apoptosis and sensitivity to chemotherapy in patient-derived GBM cells and established GBM cell lines. Results: NFIA enhanced apoptosis evasion by activating NFκB p65 and its downstream anti-apoptotic factors tumor necrosis factor receptor-associated factor 1 (TRAF1) and cellular inhibitor of apoptosis proteins (cIAPs). Induction of NFκB by NFIA was required to protect cells from apoptosis, and inhibition of NFκB effectively reversed the NFIA anti-apoptotic effect. Conversely, NFIA knockdown decreased expression of NFκB and anti-apoptotic genes TRAF1 and cIAPs, and increased baseline apoptosis. NFIA positively regulated NFκB transcription and NFκB protein level. Interestingly, NFκB also activated the NFIA promoter and increased NFIA level, and knockdown of NFIA was sufficient to attenuate the NFκB pro-survival effect, suggesting a reciprocal regulation between NFIA and NFκB in governing GBM cell survival. Supporting this, NFIA and NFκB expression levels were highly correlated in human GBM and patient-derived GBM cells. Conclusions: These data define a previously unknown NFIA-NFκB feed-forward regulation that may contribute to GBM cell survival.
Background: The nuclear factor I-A (NFIA) transcription factor promotes glioma growth and inhibits apoptosis in glioblastoma (GBM) cells. Here we report that the NFIA pro-survival effect in GBM is mediated in part via a novel NFIA-nuclear factor-kappaB (NFκB) p65 feed-forward loop. Methods: We examined effects of gain- and loss-of-function manipulations of NFIA and NFκB p65 on each other's transcription, cell growth, apoptosis and sensitivity to chemotherapy in patient-derived GBM cells and established GBM cell lines. Results:NFIA enhanced apoptosis evasion by activating NFκB p65 and its downstream anti-apoptotic factors tumor necrosis factor receptor-associated factor 1 (TRAF1) and cellular inhibitor of apoptosis proteins (cIAPs). Induction of NFκB by NFIA was required to protect cells from apoptosis, and inhibition of NFκB effectively reversed the NFIA anti-apoptotic effect. Conversely, NFIA knockdown decreased expression of NFκB and anti-apoptotic genes TRAF1 and cIAPs, and increased baseline apoptosis. NFIA positively regulated NFκB transcription and NFκB protein level. Interestingly, NFκB also activated the NFIA promoter and increased NFIA level, and knockdown of NFIA was sufficient to attenuate the NFκB pro-survival effect, suggesting a reciprocal regulation between NFIA and NFκB in governing GBM cell survival. Supporting this, NFIA and NFκB expression levels were highly correlated in human GBM and patient-derived GBM cells. Conclusions: These data define a previously unknown NFIA-NFκB feed-forward regulation that may contribute to GBM cell survival.
Authors: Francesco Fazi; Alessandro Rosa; Alessandro Fatica; Vania Gelmetti; Maria Laura De Marchis; Clara Nervi; Irene Bozzoni Journal: Cell Date: 2005-12-02 Impact factor: 41.582
Authors: G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger Journal: J Neurosurg Date: 2006-07 Impact factor: 5.115
Authors: Peng Kang; Hyun Kyoung Lee; Stacey M Glasgow; Meggie Finley; Tataka Donti; Zachary B Gaber; Brett H Graham; Aaron E Foster; Bennett G Novitch; Richard M Gronostajski; Benjamin Deneen Journal: Neuron Date: 2012-04-12 Impact factor: 17.173
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Vineshkumar Thidil Puliyappadamba; Sharmistha Chakraborty; Sandili S Chauncey; Li Li; Kimmo J Hatanpaa; Bruce Mickey; Shayan Noorani; Hui-Kuo G Shu; Sandeep Burma; David A Boothman; Amyn A Habib Journal: Cell Rep Date: 2013-08-22 Impact factor: 9.423
Authors: Emilie T Théberge; Jessica A Baker; Candis Dubose; Julia K Boyle; Kristina Balce; Dan Goldowitz; Kristin M Hamre Journal: Alcohol Clin Exp Res Date: 2019-02-12 Impact factor: 3.455
Authors: Bo Yang; Zhi-Hang Zhou; Li Chen; Xiang Cui; Jun-Yan Hou; Kai-Jie Fan; Si-Hao Han; Peng Li; Shao-Qiong Yi; Yang Liu Journal: Cancer Med Date: 2018-03-25 Impact factor: 4.452
Authors: Tou Yia Vue; Rahul K Kollipara; Mark D Borromeo; Tyler Smith; Tomoyuki Mashimo; Dennis K Burns; Robert M Bachoo; Jane E Johnson Journal: Glia Date: 2020-06-23 Impact factor: 7.452
Authors: Alisha T Poole; Christopher A Sitko; Caitlin Le; Christian C Naus; Bryan M Hill; Eric A C Bushnell; Vincent C Chen Journal: J Enzyme Inhib Med Chem Date: 2020-12 Impact factor: 5.051